• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Survival of immunobiological drugs in psoriasis: preliminary data from a Tertiary Hospital experience in Southern Brazil.

作者信息

Lima Elis Costa de, Boza Juliana Catucci, Palominos Penélope Esther, Xavier Ricardo Machado, Cestari Tania Ferreira

机构信息

Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

Department of Dermatology, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.

出版信息

An Bras Dermatol. 2021 May-Jun;96(3):376-379. doi: 10.1016/j.abd.2020.08.011. Epub 2021 Mar 15.

DOI:10.1016/j.abd.2020.08.011
PMID:33789818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8178523/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9d/8178523/b6e759ef751f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9d/8178523/b6e759ef751f/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f9d/8178523/b6e759ef751f/gr1.jpg

相似文献

1
Survival of immunobiological drugs in psoriasis: preliminary data from a Tertiary Hospital experience in Southern Brazil.免疫生物药物在银屑病中的留存率：巴西南部一家三级医院的初步数据
An Bras Dermatol. 2021 May-Jun;96(3):376-379. doi: 10.1016/j.abd.2020.08.011. Epub 2021 Mar 15.
2
COVID-19 and systemic therapies in psoriasis: experience of a tertiary hospital in Madrid.新型冠状病毒肺炎与银屑病的全身治疗：马德里一家三级医院的经验
Int J Dermatol. 2020 Nov;59(11):1425-1426. doi: 10.1111/ijd.15157. Epub 2020 Sep 4.
3
Secukinumab survival and long-term efficacy in patients with plaque psoriasis: real-life data from a tertiary hospital in Greece.司库奇尤单抗治疗斑块状银屑病患者的生存率和长期疗效：来自希腊一家三级医院的真实数据。
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e82-e84. doi: 10.1111/jdv.15231. Epub 2018 Sep 25.
4
Clinical experience of adalimumab in the treatment of psoriasis - A 10-year journey in a tertiary dermatology centre.阿达木单抗治疗银屑病的临床经验——在一家三级皮肤病中心的十年历程
Indian J Dermatol Venereol Leprol. 2018;84(2):205-208. doi: 10.4103/ijdvl.IJDVL_163_17.
5
Psoriasis in moderate grave plaque - immunobiological treatment.中度至重度斑块状银屑病——免疫生物学治疗
Rev Assoc Med Bras (1992). 2019 May 2;65(4):493-508. doi: 10.1590/1806-9282.65.4.493.
6
Psoriasis comorbidities: complications and benefits of immunobiological treatment.银屑病合并症：免疫生物治疗的并发症与益处
An Bras Dermatol. 2016 Nov-Dec;91(6):781-789. doi: 10.1590/abd1806-4841.20165080.
7
A Chinese cream (fù suo) for psoriasis.一种用于治疗牛皮癣的中国乳膏（肤锁）
Dermatology. 1996;192(3):294. doi: 10.1159/000246393.
8
Drug survival and safety profile of acitretin monotherapy in patients with psoriasis: A multicenter retrospective study.阿维 A 单药治疗银屑病患者的药物生存和安全性概况：一项多中心回顾性研究。
Dermatol Ther. 2021 Mar;34(2):e14834. doi: 10.1111/dth.14834. Epub 2021 Feb 16.
9
Real-life efficacy and safety of secukinumab: results from a tertiary hospital in Greece.司库奇尤单抗在实际应用中的疗效和安全性：来自希腊一家三级医院的结果。
J Eur Acad Dermatol Venereol. 2019 Feb;33(2):e50-e51. doi: 10.1111/jdv.15165. Epub 2018 Jul 17.
10
Real-world NHS drug survival and efficacy data for Secukinumab in chronic plaque psoriasis.苏金单抗治疗慢性斑块状银屑病的英国国家医疗服务体系（NHS）真实世界药物生存及疗效数据。
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e716-e718. doi: 10.1111/jdv.16538. Epub 2020 Jun 4.

引用本文的文献

1
Elevated serum IL-6 levels predict treatment interruption in patients with moderate to severe psoriasis: a 6-year real-world cohort study.血清 IL-6 水平升高可预测中重度银屑病患者的治疗中断：一项 6 年真实世界队列研究。
An Bras Dermatol. 2024 Jan-Feb;99(1):34-42. doi: 10.1016/j.abd.2023.03.002. Epub 2023 Aug 25.

本文引用的文献

1
Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).阿达木单抗、乌司奴单抗和司库奇尤单抗在银屑病患者中的药物留存率：一项来自英国皮肤科医师协会生物制剂与免疫调节剂登记处（BADBIR）的前瞻性队列研究。
Br J Dermatol. 2020 Aug;183(2):294-302. doi: 10.1111/bjd.18981. Epub 2020 Mar 30.
2
Real-world evidence of secukinumab in psoriasis treatment - a meta-analysis of 43 studies.司库奇尤单抗治疗银屑病的真实世界证据——43项研究的荟萃分析
J Eur Acad Dermatol Venereol. 2020 Jun;34(6):1174-1185. doi: 10.1111/jdv.16180. Epub 2020 Feb 18.
3
Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).
银屑病二线生物疗法药物生存差异：来自英国皮肤科医师协会生物干预注册处（BADBIR）的观察性队列研究。
J Invest Dermatol. 2018 Apr;138(4):775-784. doi: 10.1016/j.jid.2017.09.044. Epub 2017 Dec 6.
4
Drug survival of biologic treatments in psoriasis: a systematic review.银屑病生物治疗的药物生存期：一项系统评价
J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10.
5
Biologic drug survival in Israeli psoriasis patients.以色列银屑病患者的生物药物存活情况。
J Am Acad Dermatol. 2017 Apr;76(4):662-669.e1. doi: 10.1016/j.jaad.2016.10.033. Epub 2016 Dec 28.
6
Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).在一个基于疾病的大型银屑病患者登记系统中生物疗法的药物留存率：来自银屑病纵向评估与登记系统（PSOLAR）的结果
J Eur Acad Dermatol Venereol. 2016 Jul;30(7):1148-58. doi: 10.1111/jdv.13611. Epub 2016 Mar 30.
7
ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice.ORBIT（银屑病生物治疗的结局和保留率）：一项关于生物药物在日常实践中生存情况的回顾性观察研究。
J Am Acad Dermatol. 2016 Jun;74(6):1066-72. doi: 10.1016/j.jaad.2016.01.037. Epub 2016 Mar 19.
8
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).来自银屑病纵向评估与注册研究（PSOLAR）的优特克单抗及其他银屑病治疗药物的安全性监测
J Drugs Dermatol. 2015 Jul;14(7):706-14.
9
Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR).生物制剂治疗银屑病的药物生存差异：来自英国皮肤病学家生物干预登记处（BADBIR）的前瞻性观察队列研究。
J Invest Dermatol. 2015 Nov;135(11):2632-2640. doi: 10.1038/jid.2015.208. Epub 2015 Jun 8.
10
Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.比较寻常型银屑病患者使用生物制剂的长期药物生存和安全性。
Br J Dermatol. 2015 Jan;172(1):244-52. doi: 10.1111/bjd.13343. Epub 2014 Nov 30.